The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 5 of the 62 sources its claims cite were checked for support.
Leptin is an effective treatment for hypothalamic amenorrhea
Open accessAbstract
Hypothalamic amenorrhea (HA) is associated with dysfunction of the hypothalamic-pituitary-peripheral endocrine axes, leading to infertility and bone loss, and usually is caused by chronic energy deficiency secondary to strenuous exercise and/or decreased food intake. Energy deficiency also leads to hypoleptinemia, which has been proposed, on the basis of observational studies as well as an open-label study, to mediate the neuroendocrine abnormalities associated with this condition. To prove definitively a causal role of leptin in the pathogenesis of HA, we performed a randomized, double-blinded, placebo-controlled trial of human recombinant leptin (metreleptin) in replacement doses over 36 wk in women with HA. We assessed its effects on reproductive outcomes, neuroendocrine function, and bone metabolism. Leptin replacement resulted in recovery of menstruation and corrected the abnormalities in the gonadal, thyroid, growth hormone, and adrenal axes. We also demonstrated changes in markers of bone metabolism suggestive of bone formation, but no changes in bone mineral density were detected over the short duration of this study. If these data are confirmed, metreleptin administration in replacement doses to normalize circulating leptin levels may prove to be a safe and effective therapy for women with HA.
Overview
CoChat Summary
## TL;DR
In this 36-week randomized, double-blind, placebo-controlled trial, metreleptin improved reproductive and neuroendocrine outcomes in women with hypothalamic amenorrhea (HA). The paper concludes that hypoleptinemia likely contributes to HA-related abnormalities and that physiologic leptin replacement may be an effective therapy.
## Key findings
- Menstruation returned in 7 of 10 metreleptin-treated subjects versus 2 of 9 placebo-treated subjects (P = 0.0046); 4 of the menstruating metreleptin-treated subjects were ovulatory by midluteal progesterone (>10 ng/mL).
- Metreleptin increased reproductive hormones: estradiol and progesterone were significantly higher than placebo (P = 0.0137 and P = 0.0342, respectively); the Discussion also states estradiol, progesterone, and fT3 increased while cortisol decreased.
- Leptin replacement altered endocrine and bone markers: cortisol declined with metreleptin (P = 0.019 by treatment effect), IGF1:IGFBP-3 increased (P = 0.035), osteocalcin increased (P = 0.0019), and urinary NTX:creatinine increased less than in placebo (P = 0.0282 by treatment effect).
- Body fat fell with metreleptin: mean loss of 2.02 kg of fat, with significant effects on total body fat mass (P = 0.023) and body fat percentage (P = 0.014); resting energy expenditure did not differ significantly (P = 0.78).
## Methods
- Randomized, double-blinded, placebo-controlled trial of human recombinant leptin (metreleptin) over 36 weeks, with a week 52 follow-up after withdrawal.
- Eligible participants were women aged 18–35 years with secondary hypothalamic amenorrhea for at least 6 months associated with strenuous exercise and/or low body weight; 20 participants were enrolled, with 11 assigned to metreleptin and 9 to placebo.
- Main analyses used repeated-measures ANOVA for longitudinal outcomes; Fisher’s exact test was used for menstruation outcomes, and the paper reports last-observation-carried-forward analyses (with on-treatment analyses yielding similar results).
## Limitations
- The paper states that 36 weeks was probably not long enough to detect changes in bone mineral density (BMD), and an open-label extension was planned to assess up to 2 years of treatment.
- The paper states that measures of energy expenditure and food intake were limited: it measured resting rather than total energy expenditure, and 3-day food diaries may not have been sensitive enough.
- The paper states an early withdrawal rate of 10% by week 20 and 35% by week 36; evident from the text, the study was small (20 participants), and some outcomes were based on fewer subjects because of withdrawals and missing serum for antibody testing (e.g., antileptin antibodies in 8 of 10 metreleptin-treated and 7 of 9 placebo-treated subjects).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 23 Not checked · 127 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We fi rst showed that acutely depriving mice and then healthy men of energy by caloric restriction resulted in relative leptin de fi ciency and neuroendocrine abnormalities affecting the gonadal and thyroid axes, and these abnormalities were prevented with recombinant methionyl human leptin (metreleptin) replacement (11, 12).”
What the sources say
- Not checked yetcites [11] source
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
Our copy supports the human half of the claim: the abstract and Results (pp. 1409-1414) report that a 72-hour fast in six to eight healthy lean men produced a fall in leptin with decreased testosterone (~40%) and suppressed LH pulsatility and altered HPT-axis indices, and that replacement-dose r-metHuLeptin prevented these changes (Discussion: 'in part' for the HPT axis, so the thyroid effect is partial rather than complete). The mice component is not this paper's own finding — the Discussion (Figure 4 section) states that food deprivation lowers testosterone in male mice and that exogenous leptin restores testosterone and LH in fasted mice citing reference 8, and the Introduction likewise credits the mouse leptin-replacement data to reference 8 (Ahima et al. 1996, Nature 382:250-252). Also, the paradigm in our copy is acute total fasting, not 'caloric restriction' as the citing sentence frames it. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We fi rst showed that acutely depriving mice and then healthy men of energy by caloric restriction resulted in relative leptin de fi ciency and neuroendocrine abnormalities affecting the gonadal and thyroid axes, and these abnormalities were prevented with recombinant methionyl human leptin (metreleptin) replacement (11, 12).”
What the sources say
- Not checked yetcites [11] source
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The abstract (p. 1409) and Discussion support the human half: replacement-dose r-metHuLeptin given during a 72-hour fast to six to eight healthy lean men 'prevents the starvation-induced changes in the hypothalamic-pituitary-gonadal axis and, in part, the hypothalamic-pituitary-thyroid axis.' Two parts are not this paper's own finding: the mouse component is only mentioned in the Introduction as work credited to its reference 8 ('the role of leptin in physiologic replacement doses prevents the fasting-induced changes of several neuroendocrine axes (8), but this has not yet been directly studied in humans'), and the blanket 'the neuroendocrine abnormalities ... are prevented' overstates the source, which reports protection only for the gonadal and, partially, thyroid axes — r-metHuLeptin did not reverse the fasting-induced changes in T3/rT3, and HPA, renin-aldosterone and GH/IGF-1 changes plus fuel utilization were leptin-independent. Note also the source used acute 72-hour fasting rather than the caloric restriction the citing sentence names. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies have shown that short-term starvation of mice (11) and humans (12, 21, 22) results in hypoleptinemia and alterations in the reproductive, thyroid, and growth hormone axes, which are normalized with exogenous administration of leptin.”
What the sources say
- Not checked yetcites [11] source
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Results and Discussion report that short-term fasting in healthy men lowers leptin and alters the reproductive, thyroid, and GH–IGF-1 axes. However, the citing sentence also says exogenous leptin normalizes these changes: the paper reports restoration of reproductive measures and partial effects on thyroid measures, but says leptin did not prevent fasting-induced changes in GH pulsatility or free IGF-1. (LLM, conf=0.88)
- Not checked yetcites [21] source
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The introduction reports that leptin falls acutely during caloric deficit in animals and humans, and the paper’s fasting results describe changes in reproductive, thyroid, and GH-related measures. However, the citing sentence also says these changes are normalized by leptin: the GH and IGF-I section reports no significant difference between leptin and placebo, and the Discussion says leptin did not prevent fasting-induced GH-axis changes. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Except for one participant who was removed from the study because of weight loss at week 28, all participants in both the metreleptin- and placebo-treated groups maintained stable weights during the study with dose adjustments (Fig. 1 A and Table 2 and Table S3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fat loss occurred in both peripheral and central fat compartments.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
62 more claims
Create a free account to see all 154 claims and to verify the 57 references still open.
- Probably not a substantial claim. 56
- It may state two separate claims as one. 45
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“All these changes would be expected to have beneficial effects on bone formation and bone mass.”
From Effects of Leptin on the Skeleton (2018) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“The duration of metreleptin treatment in our previous studies was probably too short to allow for changes in BMD to manifest [18,19].”
From Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women (2011) · cites this paper as [18]
In the citing paper
“We have previously shown that increasing leptin concentrations in women with hypothalamic amenorrhea by administering exogenous recombinant methionyl human leptin (metreleptin) leads to resumption of ovulatory menses and improves many of the underlying metabolic and neuroendocrine abnormalities [18,19].”
From Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women (2011) · cites this paper as [18]
In the citing paper
“One subject randomized to receive metreleptin was withdrawn from the study after the baseline visit (shown with asterisk in Fig. 1) and was thus excluded from all analyses [18].”
From Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women (2011) · cites this paper as [18]
In the citing paper
“In addition, we found that metreleptin treatment significantly increases circulating levels of bone formation markers and/or decreases circulating levels of bone resorption markers [18,19].”
From Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women (2011) · cites this paper as [18]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Self-citationCongenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15693 · Cited by 1,320
Self-citationFarooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105
Self-citationRecombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Self-citationThomas, T., Gori, F., Khosla, S., Jensen, M. D., Burguera, B., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6637 · Cited by 726
Chan, J. L., Heist, K., DePaoli, A. M., Veldhuis, J. D., & Mantzoros, C. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17490 · Cited by 697
Self-citation
Cited by
What we talk about when we talk about fat
Rosen, E. D., & Spiegelman, B. M. (2014) · Cell · doi:10.1016/j.cell.2013.12.012 · Cited by 2,373
Mountjoy, M., Sundgot-Borgen, J., Burke, L., Carter, S., Constantini, N., Lebrun, C., Meyer, N., Sherman, R., Steffen, K., Budgett, R., et al. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2014-093502 · Cited by 1,469
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Kisspeptins and Reproduction: Physiological Roles and Regulatory Mechanisms
Pinilla, L., Aguilar, E., Dieguez, C., Millar, R. P., & Tena-Sempere, M. (2012) · Physiological Reviews · doi:10.1152/physrev.00037.2010 · Cited by 801
Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism
Park, H.-K., & Ahima, R. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.08.004 · Cited by 669
Metadata
- Authors
- Chou, S. H., Chamberland, J. P., Liu, X., Matarese, G., Gao, C., Stefanakis, R., Brinkoetter, M. T., Gong, H., Arampatzi, K., & Mantzoros, C. S.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- MultiMedica (IT)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-04-04
- Volume
- 108
- Issue
- 16
- Pages
- 6585-6590
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3080974
- OpenAlex
- W1966218936
- Semantic Scholar
- 8490bb87a04f76156fe2f8fabe5e5190cc711d34
- Cited by
- 287
- References
- 48
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 18 · 2023: 14 · 2022: 16 · 2021: 14 · 2020: 20 · 2019: 20 · 2018: 15 · 2017: 18 · 2016: 16 · 2015: 23 · 2014: 38 · 2013: 29 · 2012: 18
- FWCI
- 34.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amylin Pharmaceuticals
- Harvard Catalyst (UL1-RR025758, RR025758, M01-RR-01032)
- European Commission
- National Institute on Aging (R01AG032030, AG032030.)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK079929, R01DK058785, R56DK058785, DK 79929, DK 58785, DK 81913, K24DK081913)
- National Center for Research Resources (M01RR001032, UL1RR025758)
- FP7 Ideas: European Research Council (202579)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- hypothalamic amenorrhea, leptin, metreleptin, leptin replacement therapy, hypoleptinemia, energy deficiency, physical activity, infertility, bone metabolism, bone formation, bone mineral density, neuroendocrine function, menstrual recovery
- MeSH terms
- Adolescent, Adult, Amenorrhea, Feeding and Eating Disorders, Eating, Female, Humans, Hypothalamic Diseases, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Time Factors, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leptin is an effective treatment for hypothalamic amenorrhea. https://app.cochat.ai/papers/10.1073/pnas.1015674108
- The paper
- Chou, S. H., Chamberland, J. P., Liu, X., Matarese, G., Gao, C., Stefanakis, R., Brinkoetter, M. T., Gong, H., Arampatzi, K., & Mantzoros, C. S. (2011). Leptin is an effective treatment for hypothalamic amenorrhea. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1015674108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.